Neoadjuvant chemoimmunotherapy shows major pathological response and low recurrence in head and neck squamous cell carcinoma.
Shida YanLili LiuXing ZhangLijun WeiWenmei JiangXianlu GaoAnkui YangXuekui LiuWenkuan ChenYanfeng ChenHui LiQiaohong LinMenghua LiJingtao ChenQuan ZhangShuwei ChenMing SongPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)
Neoadjuvant chemoimmunotherapy of HNSCC showed high rate of pathological response and low recurrence rate, holding promise for becoming the new standard of care for resectable HNSCC.